Epidemiology and Pathogenesis of HIV-Associated Pulmonary Hypertension
| Status: | Active, not recruiting |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), Infectious Disease, HIV / AIDS, Hematology |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Hematology, Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/15/2018 |
| Start Date: | November 2007 |
| End Date: | June 2019 |
The purpose of this study is to describe the epidemiology of pulmonary hypertension in
individuals with HIV infection and to investigate its pathogenesis. We propose to conduct a
prospective observational cohort study to determine the association between highly active
antiretroviral therapy (HAART) and viral suppression in HIV-infected patients who have been
identified to have pre-clinical pulmonary hypertension (Aim 1). In addition, we will
investigate the mechanistic role of the HIV-1 Nef protein and HHV-8 infection in the
development and progression of pulmonary hypertension in individuals with HIV (Aim 2). We
will also investigate endothelial function in HIV-infected patients with pulmonary
hypertension (Aim 3).
individuals with HIV infection and to investigate its pathogenesis. We propose to conduct a
prospective observational cohort study to determine the association between highly active
antiretroviral therapy (HAART) and viral suppression in HIV-infected patients who have been
identified to have pre-clinical pulmonary hypertension (Aim 1). In addition, we will
investigate the mechanistic role of the HIV-1 Nef protein and HHV-8 infection in the
development and progression of pulmonary hypertension in individuals with HIV (Aim 2). We
will also investigate endothelial function in HIV-infected patients with pulmonary
hypertension (Aim 3).
Inclusion Criteria:
1. Infection with HIV greater than 6 months in duration
2. Right heart catheterization showing PASP > 30mm Hg
3. Ability to provide reliable history of HIV medications or has received the majority of
medical care from San Francisco General Hospital with available records of medical
treatment.
4. Ability to participate in follow-up for the duration of the study.
Exclusion Criteria:
1. Known significant cardiovascular disease, including clinically significant valvular
heart disease, congenital heart disease, current or prior symptomatic coronary
disease, or known cardiomyopathy.
2. Any known pulmonary disease that could potentially cause pulmonary hypertension.
3. A pO2 by pulse oximetry below 90% on room air.
4. Obstructive sleep apnea.
5. Known collagen vascular disease.
6. History of anorexigen use
- 7. Age less than 18 years old.
- 8. Other co-morbidities for which the investigators, in conjunction with the
primary care provider, believe render the participant with an expected survival
of 6 months or less.
We found this trial at
1
site
Click here to add this to my saved trials
